Description

Introduction Of Ideenat 150mg Tablet:

Ideenat 150 mg Tablet contains Idelalisib, a targeted cancer therapy medication used to treat specific types of blood cancers, such as chronic lymphocytic leukemia (CLL), follicular lymphoma, and small lymphocytic lymphoma (SLL), especially in patients who have not responded well to other treatments.

Uses Of Ideenat 150mg Tablet

Chronic Lymphocytic Leukemia (CLL)
Follicular Lymphoma
Small Lymphocytic Lymphoma (SLL)

Benefits Of Ideenat 150mg Tablet

The benefits of Ideenat 150 mg Tablet (Idelalisib) primarily relate to its effectiveness in managing certain types of blood cancers, particularly in cases where other treatments have not been successful.

Key Benefits Include

1. Targeted Cancer Therapy Idelalisib specifically targets the PI3K enzyme, which plays a vital role in the growth and survival of cancer cells. By inhibiting this enzyme, Ideenat disrupts cancer cell signaling pathways, slowing down the progression of disease while sparing normal cells to a greater extent than traditional chemotherapy.

2. Effective for Resistant or Refractory Cases It provides an option for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma, and small lymphocytic lymphoma (SLL) who have not responded well to other treatments or have relapsed. This makes Ideenat valuable for those with resistant or difficult-to-treat cancers.

Mechanism Of Action Ideenat 150mg Tablet

Targeting The Pi3k Pathway

PI3K, or phosphatidylinositol 3-kinase, is an enzyme involved in cell growth, division, and survival. In many blood cancers, the PI3K pathway is overactive, contributing to uncontrolled cancer cell growth and resistance to apoptosis (programmed cell death).Idelalisib specifically inhibits the PI3K delta isoform, which is primarily active in white blood cells (lymphocytes), including cancerous cells in conditions like chronic lymphocytic leukemia (CLL), follicular lymphoma, and small lymphocytic lymphoma (SLL).

Blocking Cancer Cell Proliferation and Survival

By inhibiting PI3K delta, Idelalisib disrupts the signaling pathways that cancer cells rely on for proliferation and survival.

This leads to reduced growth and induces apoptosis (cell death) in malignant B-cells (a type of lymphocyte), thereby controlling the progression of the cancer.